AAAAAA

   
Results: 1-10 |
Results: 10
DIFFERENTIAL INHIBITION OF P450 ISOFORMS BY HIV PROTEASE INHIBITORS
Authors: RASCA AF BONNABRY P LEEMANN T DAYER P
Citation: Af. Rasca et al., DIFFERENTIAL INHIBITION OF P450 ISOFORMS BY HIV PROTEASE INHIBITORS, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 53-53
Q-DIPS - COMPUTER-BASED PREDICTION OF KNOWN AND POTENTIAL-DRUG METABOLISM INTERACTIONS
Authors: BONNABRY P SIEVERING J LEEMANN T DAYER P
Citation: P. Bonnabry et al., Q-DIPS - COMPUTER-BASED PREDICTION OF KNOWN AND POTENTIAL-DRUG METABOLISM INTERACTIONS, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 55-55
ROLE OF HUMAN LIVER MICROSOMAL CYP2C9 IN THE BIOTRANSFORMATION OF LORNOXICAM
Authors: BONNABRY P LEEMANN T DAYER P
Citation: P. Bonnabry et al., ROLE OF HUMAN LIVER MICROSOMAL CYP2C9 IN THE BIOTRANSFORMATION OF LORNOXICAM, European Journal of Clinical Pharmacology, 49(4), 1996, pp. 305-308
STEREOSELECTIVE INHIBITION OF ACENOCOUMAROL METABOLISM BY PIROXICAM
Authors: BONNABRY P DESMEULES J LEEMANN T DAYER P
Citation: P. Bonnabry et al., STEREOSELECTIVE INHIBITION OF ACENOCOUMAROL METABOLISM BY PIROXICAM, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 87-87
ROLE OF HUMAN LIVER CYTOCHROME P450TB (CYP2C9) IN THE BIOTRANSFORMATION OF LORNOXICAM
Authors: BONNABRY P LEEMANN T DAYER P
Citation: P. Bonnabry et al., ROLE OF HUMAN LIVER CYTOCHROME P450TB (CYP2C9) IN THE BIOTRANSFORMATION OF LORNOXICAM, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 152-152
INTERACTION POTENTIAL OF NSAIDS WITH OTHER P450TB (CYP2C9) SUBSTRATES
Authors: BONNABRY P LEEMANN T DAYER P
Citation: P. Bonnabry et al., INTERACTION POTENTIAL OF NSAIDS WITH OTHER P450TB (CYP2C9) SUBSTRATES, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 158-158
SELECTIVE-INHIBITION OF MAJOR-DRUG METABOLIZING CYTOCHROME-P450 ISOZYMES IN HUMAN LIVER-MICROSOMES BY CARBON-MONOXIDE
Authors: LEEMANN T BONNABRY P DAYER P
Citation: T. Leemann et al., SELECTIVE-INHIBITION OF MAJOR-DRUG METABOLIZING CYTOCHROME-P450 ISOZYMES IN HUMAN LIVER-MICROSOMES BY CARBON-MONOXIDE, Life sciences, 54(14), 1994, pp. 951-956
BIOTRANSFORMATION BY HEPATIC P450TB (CYP2C) CONTROLS MEFENAMIC-ACID ELIMINATION
Authors: BONNABRY P LEEMANN T DAYER P
Citation: P. Bonnabry et al., BIOTRANSFORMATION BY HEPATIC P450TB (CYP2C) CONTROLS MEFENAMIC-ACID ELIMINATION, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 139-139
STEREOSELECTIVE AND NONSTEREOSELECTIVE OXIDATION BY P450TB (CYP2C) - THE MAJOR ELIMINATION PATHWAY OF (+ -)-IBUPROFEN/
Authors: LEEMANN T BONNABRY P DAYER P
Citation: T. Leemann et al., STEREOSELECTIVE AND NONSTEREOSELECTIVE OXIDATION BY P450TB (CYP2C) - THE MAJOR ELIMINATION PATHWAY OF (+ -)-IBUPROFEN/, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 208-208
A MAJOR ROLE FOR CYTOCHROME P450TB (CYP2C SUBFAMILY) IN THE ACTIONS OF NONSTEROIDAL ANTIIFLAMMATORY DRUGS
Authors: LEEMANN TD TRANSON C BONNABRY P DAYER P
Citation: Td. Leemann et al., A MAJOR ROLE FOR CYTOCHROME P450TB (CYP2C SUBFAMILY) IN THE ACTIONS OF NONSTEROIDAL ANTIIFLAMMATORY DRUGS, Drugs under experimental and clinical research, 19(5), 1993, pp. 189-195
Risultati: 1-10 |